Dr. Nolan is a tenured Professor in the Department of Microbiology and Immunology at Stanford University. He has published over 140 articles (biochemistry, gene cloning and characterization, virology immunology, transcriptional biology, bioinformatics, and signaling). He holds over a dozen patents in the biotechnology arena, and was honored as one of the top 25 inventors at Stanford University. He was the scientific founder, and was Chair of the scientific advisory board of Rigel Pharmaceuticals (a NASDAQ company); was a co-founder of the limited liability company that led to the creation of CellGate, a drug delivery company; and is the scientific Founder and Chairman of the SAB of Nodality, Inc., a venture funded company researching personalized diagnostics based on single cell interrogations of signaling networks in diseased cells. Dr. Nolan’s laboratory at the Stanford University School of Medicine focuses on the analysis of biological events at the single cell level using novel genetic and FACS-based approaches at the intersection of immunology, autoimmunity, biochemistry, and cancer.
Dr. Nolan received his Ph.D. in Genetics at Stanford University under the mentorship of Leonard and Leonore Herzenberg (co-developers of the Fluorescence Activated Cell Sorter) where he worked on the cloning of CD8 and development of the first single cell reporter gene assays. Dr. Nolan did his postdoctoral work in the laboratory of Nobelist David Baltimore at MIT. While working in the Baltimore lab, Dr. Nolan conceived and then co-developed the 293-based retroviral systems that are now a mainstay of retroviral and lentiviral production in research and gene therapy.